Four things to know · April 15, 2026
Noticed in days · Full benefit in weeks
Week 1
Typically reduced redness and irritation at application site.
Week 2-4
Commonly visible improvement in skin inflammation and texture.
Month 1-2
Significant reduction in psoriatic markers is typically observed.
Month 2-3
Sustained skin improvement is commonly reported with continued use.
Topical KPV targets skin inflammation directly. Research shows topical KPV reduced psoriatic markers by 60%. Best for psoriasis, eczema, and localized skin inflammation where systemic treatment is not needed.
Topical protocols
| Protocol | Dose | Frequency |
|---|---|---|
| Psoriasis/eczema | 0.5-1% cream | Twice daily |
| General skin inflammation | 0.5% cream | Once daily |
| Acute skin flares | 1% cream | Twice daily |
Protocols are from published research literature. This is not medical advice. Dosing should be determined by a licensed clinician.
What people report
Typically reduced redness and irritation at application site.
Commonly visible improvement in skin inflammation and texture.
Significant reduction in psoriatic markers is typically observed.
Sustained skin improvement is commonly reported with continued use.
What to know
- ⚠Patch test before first use
- ⚠For external use only
- ⚠Avoid contact with eyes and mucous membranes
- ⚠Discontinue if severe irritation occurs
Also available as
Systemic anti-inflammatory
The primary route for whole-body anti-inflammatory and immune-modulating effects. KPV injection delivers the peptide systemically for conditions affecting multiple areas, autoimmune support, and broad inflammation reduction.
Full details →OralGut inflammation and IBD/IBS
Oral KPV delivers the peptide directly to the gastrointestinal tract, making it the preferred route for inflammatory bowel disease, IBS, and gut-specific inflammation. Three distinct protocols address different levels of gut inflammation severity.
Full details →Nasal sprayChronic sinusitis relief
Nasal KPV delivers anti-inflammatory action directly to the sinus passages for chronic sinusitis and nasal inflammation. Targets the source of sinus inflammation without systemic exposure.
Full details →How KPV works
Most anti-inflammatory compounds work on the surface of cells. KPV is small enough to pass through the membrane and reach the nucleus, where it blocks NF-κB, one of the body's main inflammation switches. That inside-out approach is why it's being studied for conditions where inflammation is deep and persistent.
Key benefits
- ✓Reduces inflammation from inside the cell, not just the surface
- ✓Antimicrobial action alongside the anti-inflammatory effect
- ✓No skin pigmentation changes (unlike the full hormone it comes from)
- ✓Particularly promising for gut and skin inflammation
Regulatory status
Category 2. The FDA's pharmacy compounding advisory committee is scheduled to review KPV on July 23, 2026, for potential addition to the 503A bulks list. The uses under review: wound healing and inflammatory conditions.
KEY RESEARCH · 6 PAPERS CITED
The Pep Dispatch
Follow the evidence on KPV as it evolves.
Subscribe to find out what.
Next dispatch · May 2026 · Honest frequency: a few times a month
For the people who want to feel better — not just look up symptoms.